BB Biotechs building blocks

BB Biotech shares were listed on the Swiss stock exchange on December 27, 1993. Initial market capitalization was around CHF 340 million. Currently, BB Biotech has more than CHF 3.5 billion, making it one of the largest biotech investors in the world. Including the dividend, the share has had a total return of more than 2000% in CHF since its stock market debut. 

This performance is based on BB Biotech's portfolio of up to 35 biotechnology companies active in the growth market of innovative medicines. The experienced and highly specialized investment team not only focuses on established areas such as oncology, rare diseases and neurological indications, but also focuses early on future technologies that may offer novel treatments with a promising therapeutic profile and economic benefit. These include technologies such as RNA platforms or cell- or gene-based therapies.

Learn more about our success factors pioneering spirit, growth and know-how.

Exploring opportunities

read more

Exploring opportunities

Attractive biotech companies

read more

Attractive biotech companies

Experienced management team

read more

Experienced management team

Latest News

Media releases / 26.04.2019

Strong 1st quarter for BB Biotech

Media releases / 26.04.2019

Ad hoc release

Media releases / 11.04.2019

Completion of the current share buyback program

Media releases / 21.03.2019

Results Annual General Meeting

Media releases / 15.02.2019

Publication annual report